a cited comparison → two approved paths
PT-141 vs flibanserin: comparing the two approved HSDD medications
Same target condition, two very different mechanisms — one taken as-needed, one taken daily. Here is how they line up, cited to source.
In plain English
Here is PT-141 vs flibanserin in a nutshell. Both are FDA-approved to treat HSDD (low sexual desire that causes real distress) in premenopausal women — the only two medicines with that approval — and they work in completely different ways [How A, Simon JA, 2025]. PT-141 (bremelanotide) is a melanocortin agonist you take as needed, before activity, by injection [6]. Flibanserin is a daily pill that acts on brain serotonin and dopamine systems. Testosterone is sometimes used off-label as a third option [Vereecken S, et al., 2025]. This page compares them at a high level, cited to source — it does not tell you which to use.
Same condition, two different mechanisms
The core difference is how and when. PT-141 is the other approved HSDD medication's opposite in rhythm: it is a melanocortin MC3R/MC4R agonist taken as needed, on demand, before anticipated activity, and it acts on the brain's desire circuitry [1][6]. Flibanserin, the other approved HSDD medication, is taken daily on an ongoing basis and works through serotonin and dopamine signaling rather than the melanocortin system.
That as-needed-versus-daily contrast shapes everything downstream — how the medicine fits into life, how its side effects show up, and how its benefit is felt. A 2025 comparative analysis set bremelanotide, flibanserin, and testosterone side by side for female sexual dysfunction, contrasting their effect profiles [Vereecken S, et al., 2025], and a 2025 review of novel pharmacologic treatments placed both approved drugs among current and emerging options [How A, Simon JA, 2025]. Note: neither of these is a PDE-5 inhibitor; those treat erectile blood flow in men and are a different category entirely.
How they compare on benefit and tolerability
On the PT-141 side, the cited evidence is the 1.75 mg as-needed dose meeting both Phase 3 endpoints in 1,267 women — FSFI-desire +0.35 and FSDS-DAO item 13 −0.33 versus placebo [3] — with nausea (~40% long-term), flushing (~21%), and headache (~12%) as the leading adverse events, plus a transient blood-pressure caution [4][6]. An independent re-analysis frames PT-141's effect as small [10]; we carry that caveat openly.
We do not assign matching trial numbers to flibanserin here, because this site's cited record is built around the bremelanotide literature — putting invented head-to-head figures on the page would be the opposite of honest. What the comparative literature does is contrast the profiles: an as-needed injection with a fast, nausea-led tolerability signature versus a daily oral agent, with testosterone as an off-label third path [Vereecken S, et al., 2025]. Recent multidisciplinary recommendations on evaluating and managing HSDD discuss the evidence-based use of the approved options together [Rowen T, et al., 2026]. For the cost side of PT-141 specifically, see how it compares to other HSDD therapies on the tolerability page; for the underlying trials, see the RECONNECT Phase 3 trials.